Glycerol Tributyrate

Phase 2Small molecule

GGeorge Washington University

Glycerol Tributyrate is one of 4 small molecule programs targeting Lactic Acidosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lactic AcidosisRecruiting

Lactic AcidosisPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Lactic Acidosis

#DrugCompanyPhaseTrials

Ziagen

GSK

Approved

—2

Zerit

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

—3

Glycerol Tributyrate

GGeorge Washington University

Phase 2

1 4

Dichloroacetate

SSaol Therapeutics Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Recruiting

Lactic Acidosis

NCT06792500

Clinical

Trials by Indication[1]

Lactic Acidosis1 trial

A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)

Recruiting·GGeorge Washington University·Phase 1/2·NCT06792500·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Glycerol Tributyrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Glycerol Tributyrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Glycerol Tributyrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — George Washington University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGeorge Washington University

Glycerol Tributyrate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Lactic Acidosis1 trial

References

Drug Info

Quick Facts

Related News